GSK, one of the UK’s leading pharmaceutical companies, has committed up to $2 billion to acquire a promising new liver disease drug from Boston Pharmaceuticals. The latest acquisition aims to
GSK, one of the UK’s leading pharmaceutical companies, has committed up to $2 billion to acquire a promising new liver disease drug from Boston Pharmaceuticals. The latest acquisition aims to






